Xanthohumol

DIETARY_SUPPLEMENT7 trials

Sponsors

Oregon State University, National University of Natural Medicine, Medical University of Lublin, University of Vienna

Conditions

ARDSCrohn DiseaseHealthyInfection ViralInflammatory ResponseMetabolic SyndromePneumoniaSeptic Shock

Phase 1

Xanthohumol Metabolism and Signature

Active, not recruitingNCT03735420

National University of Natural MedicineHealthy

Start: 2019-08-12End: 2024-12-31Updated: 2024-08-27

Phase 2

A Phase 2 Clinical Trial: Xanthohumol Metabolism and Signature (XMaS) in Crohn's Disease

Active, not recruitingNCT04590508

National University of Natural MedicineCrohn Disease

Start: 2020-10-01End: 2025-07-30Updated: 2024-10-18

Xanthohumol as an Adjuvant in the Treatment of Septic Shock

RecruitingNCT06225258

Medical University of LublinARDS, Pneumonia, Septic Shock

Start: 2023-01-09End: 2025-12-31Target: 50Updated: 2025-07-04

Unknown Phase

Xanthohumol and Metabolic Syndrome

CompletedNCT01367431

Oregon State UniversityMetabolic Syndrome

Start: 2011-08-31End: 2012-04-30Updated: 2015-07-24

Hop Compounds on the Immune System (VH)

RecruitingNCT06286644

University of ViennaInflammatory Response

Start: 2022-05-30End: 2025-12-30Target: 14Updated: 2025-04-15

Xanthohumol and Viral Infections (XL)

RecruitingNCT06286657

University of ViennaInfection Viral

Start: 2023-08-01End: 2025-12-30Target: 100Updated: 2025-04-15

Hop Compounds on the Immune System in Overweight People

RecruitingNCT06745102

University of ViennaInflammatory Response

Start: 2024-02-01End: 2025-12-30Target: 24Updated: 2025-04-15

Related Papers

Gut enterotype-dependent modulation of gut microbiota and their metabolism in response to xanthohumol supplementation in healthy adults

Gut Microbes2024-02-1516 citations

Xanthohumol microbiome and signature in adults with Crohn's disease (the XMaS trial): a protocol for a phase II triple-masked, placebo-controlled clinical trial.

2022-10-2210 citations

Xanthohumol microbiome and signature in healthy adults (the XMaS trial): a phase I triple-masked, placebo-controlled clinical trial.

2020-10-0714 citations